Hepatitis

07/05/1992 - "Until now various antiviral and immunomodulatory agents were administered in chronic type B hepatitis, recently the most promising results were reported using recombinant interferons. "
06/01/2012 - "Interferon is used to treat chronic viral hepatitis because of low drug resistance and a high remission rate. "
06/01/2008 - "The antiviral treatment of chronic C hepatitis has improved significantly over the past decade with the introduction of interferons (IFNs), and more recently, pegylated IFNs. "
01/01/1994 - "In patients responding to interferon therapy there was a significant reduction in the severity of the hepatitis. "
06/01/1993 - "Interferon is useful for the treatment of chronic active anti-HCV positive hepatitis but the beneficial responses are often transient. "

01/01/2013 - "In these experimental settings, recovery from hepatitis correlates with a complete loss of OVA expression indicating efficient clearance of the antigen-expressing hepatocytes. "
08/01/1996 - "Although IFN was effective in controlling the manifestations of hepatitis in terms of e-antigen-negative patients who exhibited abnormal fluctuations in ALT, it appears that continuous treatment with intermittent high-dose IFN is necessary to maintain ALT levels within the normal range."
07/01/1978 - "Rapid clearance of HBe antigen and development of anti-HBe antibody in acute viral hepatitis."
03/01/1974 - "Improved counterimmunoelectrophoretic test for rapid detection of hepatitis-associated antigen."
01/01/2013 - "An inducible transgenic mouse model for immune mediated hepatitis showing clearance of antigen expressing hepatocytes by CD8+ T cells."

07/01/1985 - "Kinetics of synthesis of anti-pre-S antibody in the course of acute type hepatitis followed by elimination of HBsAg and recovery suggest the important role of this antibody in immunological neutralization and clearance of infective HBV particles. "
05/01/2007 - "In multivariate analysis, the probability of HBsAg seroclearance correlated positively with age at entry (P<0.0001) and sustained remission of hepatitis (P<0.0001) and marginally significantly with male sex (P=0.053). "
03/26/1999 - "Concerning the vaccination impact on HBV endemicity in Italy, we found a significant reduction of acute viral hepatitis incidence (4.2/100,000 in 1996 versus 19/100,000 in the '80s) and HBsAg carrier prevalence (0.9% in 1997 versus 3% in the '80s). "
09/18/1976 - "Hepatitis B surface antigen (HBsAg) was cleared from the serum significantly faster (P less than 0-001) in those with fulminant hepatitis, and in 41% anti-HBsAg (HBsAb) was detectable by radioimmunoassay (RIA) at presentation. "
01/01/1976 - "The results suggest that an unusually strong and rapid immune clearance of HBSAg may be involved in the pathogenesis of fulminant hepatitis."

09/01/2002 - "Overall, although it appears that interferon-alpha therapy is beneficial in the prevention of HCC in patients with viral hepatitis, more experience is required before definitive recommendations can be made."
04/01/2000 - "Lack of efficacy and significant side effects have severely limited the use of interferon-alpha (IFN-alpha) as the standard therapy for non-A non-B hepatitis (NANBH) caused by hepatitis C virus (HCV) and alternative, improved therapies are urgently sought. "
05/01/1998 - "5% cases had fulminant viral Hepatitis (FVH)/Sub fulminant viral Hepatitis (SVH), alpha-interferon (IFN) has been proved beneficial in these cases, further use of intravenous PGEl could also be beneficial. "
01/01/1995 - "alpha-Interferon is effective in inhibiting viral replication in a significant number of patients with chronic type B hepatitis, but new therapeutic regimens and a better selection of patients are needed in order to induce persistent remissions and reduce the cost/benefit ratio."
04/01/1994 - "In conclusion, human lymphoblastoid interferon-alpha treatment for one year is beneficial in patients suffering from chronic sporadic-type non-A, non-B hepatitis. "

03/01/2009 - "Lamivudine has been established as a safe and effective antiviral agent for the treatment of chronic HBV hepatitis. "
02/01/2006 - "The aim of this study was to evaluate the efficacy of preemptive lamivudine therapy in reducing hepatitis due to HBV reactivation in patients with HCC undergoing transarterial chemo-lipiodolization (TACL) and to seek predictors of this event. "
01/01/2004 - "Among patients with hepatitis reactivation, two were treated with lamivudine resulting in dramatic improvement and clinical remission of the disease. "
09/01/2015 - "The aim of the present study was to determine the prevalence of precore and lamivudine drug resistance mutations in lamivudine treated patients with chronic B hepatitis. "
07/01/2014 - "Lamivudine-withdrawal hepatitis was not detected; however, one case of breakthrough HBV reactivation during lamivudine treatment was observed in this study. "

01/01/1998 - "Therefore, in patients with CH-B who had a sustained loss of HBeAg and complete remission of hepatitis after SC, the precore region was sequenced in paired serum samples from 1 year before SC to 3 years after SC. "
01/01/1995 - "These results are consistent with the hypothesis that after clearance of HBeAg, mutations in regions of the virus recognized by CD4+ helper T cells and B cells allow persistence of the HBe negative virus in HBeAb positive patients with viraemia and active hepatitis."
09/14/2015 - "Patients were categorized into four groups based on disease status as recommended by the European Association for the Study of the Liver: immune tolerance (IT; n = 47), HBeAg-positive hepatitis (EPH; n = 93), HBeAg-negative hepatitis (ENH; n = 20), and inactive carrier (IC; n = 55). "
10/01/2014 - "We next divided patients into abnormal (≥31 IU/L, n = 20) and normal (<31 IU/L, n = 16) groups based on integrated ALT level after the time point of 2 years from SC, and considered the former group as having HBeAg negative hepatitis in the present study. "
06/01/2007 - "In addition, relapse of hepatitis was significantly less frequent in patients who were younger than 30 years at study entry, possibly implicating more favorable outcome of earlier HBeAg seroconversion."

01/01/1998 - "Mutant precore defective HBV DNA was found in only 6 (19%) of 31 CH-B patients who had a complete remission of hepatitis after SC. "
12/01/1990 - "Aggressive hepatitis in a patient with acute myeloid leukaemia during complete remission and detection of Epstein-Barr virus DNA in a liver biopsy."
05/01/1983 - "A marked decrease in the quantity of HBV DNA in the plasma during the acute phase of the non-A, non-B hepatitis was observed in both carriers. "
04/01/2012 - "Many reports maintain that regular measurement of HBV DNA is effective in preventing de novo hepatitis. "
07/01/2008 - "CLDC were effective in reducing liver HBV DNA and could be considered for further evaluation in other hepatitis models."

10/01/1996 - "It is widely believed that the hepatitis B virus (HBV) is completely cleared by antiviral antibodies and specific cytotoxic T lymphocytes (CTLs) during acute viral hepatitis. "
09/30/1978 - "The incidence of anti-HBs antibodies in the two groups of patients suggests that they are partially protective against "B" hepatitis. "
08/01/1995 - "Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: final report of a prospective trial."
12/01/1993 - "Efficacy of blood screening of donors for antibodies to hepatitis C virus in preventing post-transfusion nonA, nonB hepatitis."
05/01/1990 - "However, these auto-antibodies do not have an absolute association with auto-immune CAH: the serological reactions are not yet standardized; titres decrease with remission of disease; and other auto-antibodies mark variant forms of auto-immune hepatitis. "

01/01/2013 - "This study was designed to examine the protective effects and mechanisms of Nec-1 in concanavalin A- (ConA-) induced hepatitis in mice. "
09/01/2011 - "Roles of platelets and macrophages in the protective effects of lipopolysaccharide against concanavalin A-induced murine hepatitis."
09/15/2013 - "C57BL/6 mice were fed a diet supplemented with or without 0.3% (wt/vol) UDCA for 4 wk. UDCA improved hepatocyte injury and survival in concanavalin-A (Con-A)-induced hepatitis by suppressing IFN-γ production by liver mononuclear cells (MNC), especially NK and NKT cells. "
01/01/2012 - "Efficacy of adipose tissue-derived mesenchymal stem cells for fulminant hepatitis in mice induced by concanavalin A."
10/01/2009 - "Inhibition of phosphodiesterase 7A ameliorates Concanavalin A-induced hepatitis in mice."

01/01/2016 - "In acute hepatitis patients who eventually cleared HBV, IDO activity, chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10, and CXCL11 increased at the peak of alanine aminotransferase. "
12/01/2000 - "GB virus-B (GBV-B) causes an acute hepatitis in tamarins characterized by increased alanine transaminase levels that quickly return to normal as the virus is cleared. "
04/01/2015 - "Multiple studies have recently proposed the lowering of upper limit of normal (ULN) for alanine aminotransferase (ALT) to improve the diagnostic sensitivity for viral hepatitides and metabolic syndrome (MS). "
11/01/2008 - "This study elucidates the changing aetiology of alanine transaminase elevation (ALT levels >40 IU/L) in a previously hepatitis-endemic township. "
09/01/1998 - "In the two treatment trials, pooled analysis of the patients with mild hepatitis showed that 36.4% of them normalized serum alanine aminotransferase and remained virus negative (sustained response) after completing an 18-24 month course of IFN vs 15.3% for a 6-month course and no response in the absence of treatment. "

03/01/2001 - "Improved HBV detection tests, which appear mandatory for the diagnosis and management of non-A non-E hepatitis as well as for improved safety of transfusions and transplantations are needed."
07/01/1994 - "Of the 81 typed, 36 patients (44.4%) were found to have an HLA-matched sibling donor and 21 (25%) underwent BMT (8% of the total population); 15 patients did not undergo BMT (6 relapsed before transplantation and did not obtain a second remission, 3 declined the procedure, 1 died during induction, 1 had positive MLR, 1 had positive MLR and HCV hepatitis, 1 was a drug addict with HCV hepatitis, 1 had previous organ toxicity, 1 was psychotic). "
08/01/1992 - "Despite improvement in the care of transplant recipients, these patients are exposed to large volumes of blood and, as a result, are at risk to acquire hepatitis. "
12/01/1991 - "Five patients (18%) cleared both HBV and HDV after transplantation with no evidence of hepatitis (mean follow-up, 29 months). "
12/01/2008 - "This study was designed to explore the opportunity of RNA interference technique in the inhibitory application of hfgl2 expression, which has been reported to be involved in a variety of disease developments including fulminant viral hepatitis, acute rejection of allo/xeno transplantation and fetal loss syndrome. "

01/01/2004 - "In cases of severe acute hepatitis hospital admission should be recommended; in cases of fulminant hepatitis, admission to the intensive care unit for intensive monitoring and evaluation of a liver transplantation is recommended if spontaneous improvement does not occur. "
08/01/2007 - "Emergency adult to adult living donor liver transplantation is an effective treatment for fulminant hepatitis but the safety of the donors should be assessed strictly preoperation."
07/01/2007 - "Emergency adult living-donor liver transplantation is an effective treatment for fulminant hepatitis patients and is relatively safe for donors. "
10/01/2015 - "Spontaneous clearance of HCV accompanying hepatitis after liver transplantation."
07/01/2012 - "Living donor liver transplantation (LDLT) is the ultimate cure for fulminant hepatitis. "

02/01/2012 - "The therapeutic efficacy of integrated CM and Western medical drug therapy, by using QLD during icteric stage and YJD in nonicteric hyper-aminotransferase stage, was significantly higher than that of routine Western medical treatment alone; it was an ideal project for the treatment of infantile cytomegalovirus hepatitis."
09/01/2010 - "Consequently, he received constitutional chemotherapy in the hepatitis unit and is now in remission. "
02/01/1992 - "Both had developed posttransfusion hepatitis during chemotherapy to induce remission and for consolidation. "
12/01/2006 - "Among 1,477 patients who received chemotherapy due to various malignancies from January 2000 to June 2005, 668 patients with incomplete viral studies or hepatitis related malignancy were excluded. "
03/01/1999 - "In this study we looked for hepatotoxicity and for chronic viral hepatitis during and after chemotherapy in 50 unselected children with malignant diseases. "

04/01/1992 - "Several months later her bone marrow blast exceeded 30%, when serum B12 concentration was below 90 pg/ml. B12 injection and blood transfusion resulted in significant improvement in her hematological condition, but shortly thereafter she died of fulminant hepatitis. "
01/01/1986 - "The definition of non-A, non-B hepatitis (NANB) is improved by further characterization of what it is not (like the delta agent or non-A epidemic hepatitis) rather than by providing convincing evidence of isolation of the agent responsible for blood transfusion- or blood product-related NANB or specific markers thereof. "
01/01/2015 - "This study confirms household contact, history of dental work, history of surgery, sexual contact, and history of transfusion (blood and its components) as the main risk factors which are responsible for the increased prevalence of hepatitis. "
01/01/1996 - "Data from 13 blood transfusion centers collecting about 1 million donations per year and belonging to the Retrovirus and the Viral Hepatitis study groups were analyzed during the 3 year study period (1992-1994) for HIV, HTLV, and HBV and a 2 year study period for HCV (1993-1994). "
11/01/1995 - "In the present study, screening investigations were performed in a high risk population of HCC, defined as persons who had hepatitis, blood transfusions, a family history of HCC, and were hepatitis B virus carriers. "

11/28/2014 - "Many studies published over recent years have shown that antiviral treatment of post-transplant HCV hepatitis carried out during the late phase is the best option for improving the prognosis of these patients. "
06/01/2012 - "Despite the institution of appropriate post-exposure prophylaxis, the recipient demonstrated latent seroconversion; however, liver graft function improved without evidence of syphilitic hepatitis or other manifestations of the disease. "
04/01/2011 - "No patient or graft loss was observed among hepatitis groups when compared with disease-free patients. "
01/01/2009 - "[Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant]."
09/01/2009 - "Studies addressing exclusively transplanted HCV patients demonstrated a significant advantage of steroid-free protocols considering HCV recurrence [R.R = 1.15 (1.01, 1.13)], acute graft hepatitis [O.R = 3.15 (1.18, 8.40)], and treatment failure [O.R = 1.87 (1.33, 2.63)]. "